Hubbry Logo
Cell surface receptorCell surface receptorMain
Open search
Cell surface receptor
Community hub
Cell surface receptor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cell surface receptor
Cell surface receptor
Cell surface receptor
View on Wikipedia
from Wikipedia
The seven-transmembrane α-helix structure of a G-protein-coupled receptor

Cell surface receptors (membrane receptors, transmembrane receptors) are receptors that are embedded in the plasma membrane of cells.[1] They act in cell signaling by receiving (binding to) extracellular molecules. They are specialized integral membrane proteins that allow communication between the cell and the extracellular space. The extracellular molecules may be hormones, neurotransmitters, cytokines, growth factors, cell adhesion molecules, or nutrients; they react with the receptor to induce changes in the metabolism and activity of a cell. In the process of signal transduction, ligand binding affects a cascading chemical change through the cell membrane.

Structure and mechanism

[edit]
Main article: Receptor (biochemistry)

Many membrane receptors are transmembrane proteins. There are various kinds, including glycoproteins and lipoproteins.[2] Hundreds of different receptors are known and many more have yet to be studied.[3][4] Transmembrane receptors are typically classified based on their tertiary (three-dimensional) structure. If the three-dimensional structure is unknown, they can be classified based on membrane topology. In the simplest receptors, polypeptide chains cross the lipid bilayer once, while others, such as the G-protein coupled receptors, cross as many as seven times. Each cell membrane can have several kinds of membrane receptors, with varying surface distributions. A single receptor may also be differently distributed at different membrane positions, depending on the sort of membrane and cellular function. Receptors are often clustered on the membrane surface, rather than evenly distributed.[5][6]

Mechanism

[edit]

Two models have been proposed to explain transmembrane receptors' mechanism of action.

  • Dimerization: The dimerization model suggests that prior to ligand binding, receptors exist in a monomeric form. When agonist binding occurs, the monomers combine to form an active dimer.
  • Rotation: Ligand binding to the extracellular part of the receptor induces a rotation (conformational change) of part of the receptor's transmembrane helices. The rotation alters which parts of the receptor are exposed on the intracellular side of the membrane, altering how the receptor can interact with other proteins within the cell.[7]

Domains

[edit]
E = extracellular space
P = plasma membrane
I = intracellular space

Transmembrane receptors in plasma membrane can usually be divided into three parts.

Extracellular domains

[edit]

The extracellular domain is just externally from the cell or organelle. If the polypeptide chain crosses the bilayer several times, the external domain comprises loops entwined through the membrane. By definition, a receptor's main function is to recognize and respond to a type of ligand. For example, a neurotransmitter, hormone, or atomic ions may each bind to the extracellular domain as a ligand coupled to receptor. Klotho is an enzyme which effects a receptor to recognize the ligand (FGF23).[citation needed]

Transmembrane domains

[edit]

Two most abundant classes of transmembrane receptors are GPCR and single-pass transmembrane proteins.[8][9] In some receptors, such as the nicotinic acetylcholine receptor, the transmembrane domain forms a protein pore through the membrane, or around the ion channel. Upon activation of an extracellular domain by binding of the appropriate ligand, the pore becomes accessible to ions, which then diffuse. In other receptors, the transmembrane domains undergo a conformational change upon binding, which affects intracellular conditions. In some receptors, such as members of the 7TM superfamily, the transmembrane domain includes a ligand binding pocket.[citation needed]

Intracellular domains

[edit]

The intracellular (or cytoplasmic) domain of the receptor interacts with the interior of the cell or organelle, relaying the signal. There are two fundamental paths for this interaction:[citation needed]

  • The intracellular domain communicates via protein-protein interactions against effector proteins, which in turn pass a signal to the destination.
  • With enzyme-linked receptors, the intracellular domain has enzymatic activity. Often, this is tyrosine kinase activity. The enzymatic activity can also be due to an enzyme associated with the intracellular domain.

Signal transduction

[edit]
External reactions and internal reactions for signal transduction (click to enlarge)

Signal transduction processes through membrane receptors involve the external reactions, in which the ligand binds to a membrane receptor, and the internal reactions, in which intracellular response is triggered.[10][11]

Signal transduction through membrane receptors requires four parts:

  • Extracellular signaling molecule: an extracellular signaling molecule is produced by one cell and is at least capable of traveling to neighboring cells.[citation needed]
  • Receptor protein: cells must have cell surface receptor proteins which bind to the signaling molecule and communicate inward into the cell.[citation needed]
  • Intracellular signaling proteins: these pass the signal to the organelles of the cell. Binding of the signal molecule to the receptor protein will activate intracellular signaling proteins that initiate a signaling cascade.[citation needed]
  • Target proteins: the conformations or other properties of the target proteins are altered when a signaling pathway is active and changes the behavior of the cell.[11]
Three conformation states of acetylcholine receptor (click to enlarge)

Membrane receptors are mainly divided by structure and function into 3 classes: The ion channel linked receptor; The enzyme-linked receptor; and The G protein-coupled receptor.

  • Ion channel linked receptors have ion channels for anions and cations, and constitute a large family of multipass transmembrane proteins. They participate in rapid signaling events usually found in electrically active cells such as neurons. They are also called ligand-gated ion channels. Opening and closing of ion channels is controlled by neurotransmitters.[citation needed]
  • Enzyme-linked receptors are either enzymes themselves, or directly activate associated enzymes. These are typically single-pass transmembrane receptors, with the enzymatic component of the receptor kept intracellular. The majority of enzyme-linked receptors are, or associate with, protein kinases.[citation needed]
  • G protein-coupled receptors are integral membrane proteins that possess seven transmembrane helices. These receptors activate a G protein upon agonist binding, and the G-protein mediates receptor effects on intracellular signaling pathways.[citation needed]

Ion channel-linked receptor

[edit]
Main article: Ligand-gated ion channel

During the signal transduction event in a neuron, the neurotransmitter binds to the receptor and alters the conformation of the protein. This opens the ion channel, allowing extracellular ions into the cell. Ion permeability of the plasma membrane is altered, and this transforms the extracellular chemical signal into an intracellular electric signal which alters the cell excitability.[12]

The acetylcholine receptor is a receptor linked to a cation channel. The protein consists of four subunits: alpha (α), beta (β), gamma (γ), and delta (δ) subunits. There are two α subunits, with one acetylcholine binding site each. This receptor can exist in three conformations. The closed and unoccupied state is the native protein conformation. As two molecules of acetylcholine both bind to the binding sites on α subunits, the conformation of the receptor is altered and the gate is opened, allowing for the entry of many ions and small molecules. However, this open and occupied state only lasts for a minor duration and then the gate is closed, becoming the closed and occupied state. The two molecules of acetylcholine will soon dissociate from the receptor, returning it to the native closed and unoccupied state.[13][14]

Enzyme-linked receptors

[edit]
Main article: Enzyme-linked receptor
Sketch of an enzyme-linked receptor structure (structure of IGF-1R) (click to enlarge)

As of 2009, there are 6 known types of enzyme-linked receptors: Receptor tyrosine kinases; Tyrosine kinase associated receptors; Receptor-like tyrosine phosphatases; Receptor serine/threonine kinases; Receptor guanylyl cyclases and histidine kinase associated receptors. Receptor tyrosine kinases have the largest population and widest application. The majority of these molecules are receptors for growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), nerve growth factor (NGF) and hormones such as insulin. Most of these receptors will dimerize after binding with their ligands, in order to activate further signal transductions. For example, after the epidermal growth factor (EGF) receptor binds with its ligand EGF, the two receptors dimerize and then undergo phosphorylation of the tyrosine residues in the enzyme portion of each receptor molecule. This will activate the tyrosine kinase and catalyze further intracellular reactions.[citation needed]

G protein-coupled receptors

[edit]
Main article: G protein-coupled receptor

G protein-coupled receptors comprise a large protein family of transmembrane receptors. They are found only in eukaryotes.[15] The ligands which bind and activate these receptors include: photosensitive compounds, odors, pheromones, hormones, and neurotransmitters. These vary in size from small molecules to peptides and large proteins. G protein-coupled receptors are involved in many diseases, and thus are the targets of many modern medicinal drugs.[16]

There are two principal signal transduction pathways involving the G-protein coupled receptors: the cAMP signaling pathway and the phosphatidylinositol signaling pathway.[17] Both are mediated via G protein activation. The G-protein is a trimeric protein, with three subunits designated as α, β, and γ. In response to receptor activation, the α subunit releases bound guanosine diphosphate (GDP), which is displaced by guanosine triphosphate (GTP), thus activating the α subunit, which then dissociates from the β and γ subunits. The activated α subunit can further affect intracellular signaling proteins or target functional proteins directly.[citation needed]

[edit]

If the membrane receptors are denatured or deficient, the signal transduction can be hindered and cause diseases. Some diseases are caused by disorders of membrane receptor function. This is due to deficiency or degradation of the receptor via changes in the genes that encode and regulate the receptor protein. The membrane receptor TM4SF5 influences the migration of hepatic cells and hepatoma.[18] Also, the cortical NMDA receptor influences membrane fluidity, and is altered in Alzheimer's disease.[19] When the cell is infected by a non-enveloped virus, the virus first binds to specific membrane receptors and then passes itself or a subviral component to the cytoplasmic side of the cellular membrane. In the case of poliovirus, it is known in vitro that interactions with receptors cause conformational rearrangements which release a virion protein called VP4.The N terminus of VP4 is myristylated and thus hydrophobic【myristic acid=CH3(CH2)12COOH】. It is proposed that the conformational changes induced by receptor binding result in the attachment of myristic acid on VP4 and the formation of a channel for RNA.[citation needed]

Structure-based drug design

[edit]
Flow charts of two strategies of structure-based drug design
Main article: Drug design

Through methods such as X-ray crystallography and NMR spectroscopy, the information about 3D structures of target molecules has increased dramatically, and so has structural information about the ligands. This drives rapid development of structure-based drug design. Some of these new drugs target membrane receptors. Current approaches to structure-based drug design can be divided into two categories. The first category is about determining ligands for a given receptor. This is usually accomplished through database queries, biophysical simulations, and the construction of chemical libraries. In each case, a large number of potential ligand molecules are screened to find those fitting the binding pocket of the receptor. This approach is usually referred to as ligand-based drug design. The key advantage of searching a database is that it saves time and power to obtain new effective compounds. Another approach of structure-based drug design is about combinatorially mapping ligands, which is referred to as receptor-based drug design. In this case, ligand molecules are engineered within the constraints of a binding pocket by assembling small pieces in a stepwise manner. These pieces can be either atoms or molecules. The key advantage of such a method is that novel structures can be discovered.[20][21][22]

Other examples

[edit]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cell surface receptor

View on Grokipedia
from Grokipedia
Cell surface receptors are transmembrane proteins embedded in the plasma membrane of eukaryotic cells that bind specific extracellular ligands, such as hormones, neurotransmitters, growth factors, or components, to initiate intracellular signaling cascades that regulate diverse cellular processes including proliferation, differentiation, , and . These receptors typically consist of an extracellular ligand-binding domain, a hydrophobic spanning the (often a single α-helix or multiple helices), and an intracellular domain that interacts with signaling molecules to propagate the signal. Structural variations enable specificity: for instance, G protein-coupled receptors (GPCRs) feature seven transmembrane α-helices forming a barrel-like structure, while receptor kinases (RTKs) possess a single-pass transmembrane region and intrinsic enzymatic activity in their cytosolic tails. Cell surface receptors are classified into several major families based on their signaling mechanisms. The largest group, GPCRs, which comprise over 800 members in humans, couple to heterotrimeric G proteins to modulate second messengers like cyclic AMP or ion channels, mediating responses to light, odors, and many hormones. RTKs, numbering around 58 in humans, dimerize upon ligand binding to autophosphorylate residues, activating pathways such as MAPK/ERK for cell growth and survival; notable examples include the insulin and (EGF) receptors. Cytokine receptors lack enzymatic activity but associate with Janus kinases (JAKs) to phosphorylate STAT proteins, driving immune responses via and interferons. Other types include ligand-gated ion channels, like nicotinic receptors that directly open ion pores, and that link the to the for adhesion and mechanotransduction. Beyond signaling, some cell surface receptors facilitate ligand transport through , such as the () receptor, which internalizes cholesterol-laden particles for cellular uptake and lysosomal degradation, or the , which recycles iron via clathrin-coated pits. These dual roles underscore their importance in nutrient and receptor trafficking, where internalization can attenuate signaling or enhance accuracy by concentrating ligands. Dysregulation of cell surface receptors is implicated in numerous diseases, including cancers (e.g., EGFR mutations in ), autoimmune disorders, and metabolic syndromes, making them prime targets for therapeutics—GPCRs alone account for about 30-40% of FDA-approved drugs. Their discovery and characterization, beginning with G proteins in the 1970s and activity in the 1980s, have revolutionized understanding of cellular communication and .

Introduction

Definition and biological significance

Cell surface receptors are transmembrane proteins embedded in the plasma membrane of cells, consisting of an extracellular domain that binds specific ligands from the external environment, a hydrophobic transmembrane region spanning the , and an intracellular domain that relays signals into the cell. These receptors primarily interact with extracellular signaling molecules, such as hormones, neurotransmitters, growth factors, , and antigens, to trigger intracellular signaling cascades that modulate cellular behavior. For instance, epinephrine binds to adrenergic receptors, while engage cytokine receptors on immune cells, and antigens are recognized by T-cell or B-cell receptors. The biological significance of cell surface receptors lies in their role as essential mediators of intercellular communication, allowing cells to detect and respond to diverse environmental cues with high specificity and sensitivity. By serving as the initial point of contact for extracellular signals, they coordinate critical multicellular processes, including embryonic development, maintenance of physiological , activation, and sensory perception such as vision and olfaction. This function underscores their importance as "first responders" in , where binding induces conformational changes that propagate signals without the ligand needing to cross the . The vast diversity of these receptors—exemplified by over 800 G protein-coupled receptors (GPCRs) in the —enables tailored responses to thousands of potential signals, reflecting their adaptability in complex organisms. Evolutionarily, cell surface receptors are highly conserved across all eukaryotes, from unicellular protists to multicellular animals and plants, indicating their ancient origins and indispensable role in the of cellular signaling networks. This conservation highlights how these proteins have facilitated the transition from solitary cells to organized multicellular life, enabling coordinated responses that underpin organismal survival and adaptation.

Historical development

The concept of cell surface receptors emerged in the late through Paul Ehrlich's side-chain theory, proposed in 1897, which described cellular responses to external stimuli via specific receptor-like structures on cell surfaces, analogous to a lock-and-key mechanism in immune interactions. This theory laid foundational ideas for how cells selectively bind ligands, influencing early understandings of toxin and actions. In the mid-20th century, advances in biochemistry revealed specific hormone-binding sites on cells, marking the identification of functional receptors. During the 1940s and 1950s, radiolabeling techniques enabled the detection of high-affinity binding sites for hormones like insulin on target tissues, as demonstrated by early studies indicating receptor-mediated uptake and response. A pivotal discovery came in 1958 when Earl W. Sutherland identified cyclic AMP (cAMP) as an intracellular second messenger activated by hormone-receptor interactions, explaining signal amplification beyond the cell surface. The molecular era began with the cloning of the β-adrenergic receptor, the first (GPCR), in 1986 by Robert J. Lefkowitz and colleagues, revealing its seven-transmembrane structure and homology to . This breakthrough facilitated genetic and functional studies of GPCRs, culminating in the 2012 awarded to Lefkowitz and Brian K. Kobilka for elucidating GPCR structure and activation mechanisms. Technological innovations in provided atomic-level insights into receptors. The first crystal structure of a non-opsin GPCR, the β₂-adrenergic receptor, was solved by in 2007, building on rhodopsin's 2000 structure and enabling visualization of ligand-bound conformations. Post-2010, cryo-electron microscopy (cryo-EM) revolutionized the field by resolving dynamic GPCR-transducer complexes, such as the A₂A receptor with in 2017, overcoming limitations of crystallization for membrane proteins. In the 2020s, tools like have accelerated receptor research by predicting structures of understudied cell surface receptors, including adhesion-family GPCRs and taste receptors, with high accuracy for interactions. Concurrently, has expanded receptor engineering to non-mammalian systems, such as and , enabling programmable synthetic receptors for biosensing and therapeutic production as of 2024.

Structural organization

Extracellular domains

The extracellular domains of cell surface receptors are regions protruding into the , enabling interaction with soluble ligands, components, or other cells. These domains typically consist of folded protein motifs that form ligand-binding pockets, including immunoglobulin-like folds, leucine-rich repeats (LRRs), and cysteine-rich domains, which provide structural diversity for specific molecular recognition. For instance, LRRs, characterized by repeating sequences of 20-30 rich in , create a horseshoe-shaped scaffold for ligand interaction in receptors like Toll-like receptors. Cysteine-rich domains, often featuring disulfide-bonded loops, stabilize the architecture and facilitate dimerization in families such as receptor tyrosine kinases (RTKs). These domains mediate high-affinity binding to ligands, with dissociation constants (Kd) typically ranging from 10^{-9} to 10^{-12} M, ensuring selective recognition amid diverse extracellular signals. This affinity arises from complementary shapes and electrostatic interactions within the binding pockets, which stabilize the ligand-receptor complex and initiate receptor . Beyond binding, the extracellular domains contribute to ligand specificity by discriminating between structurally similar molecules and provide initial stabilization to prevent premature dissociation. Structural variations across receptor classes adapt the extracellular domains to specific ligands and functions. In G protein-coupled receptors (GPCRs), particularly class B subtypes, N-terminal extensions form α-helical bundles that bind peptide ligands like or . For RTKs, cysteine-rich motifs in subdomains II and IV promote ligand-induced dimerization, as seen in the Trk family where these regions flank leucine-rich cores to align receptors for signaling. sites, abundant on these domains, enhance protein stability by shielding hydrophobic regions and aiding proper folding, while in pathological contexts such as cancer, altered patterns can facilitate immune evasion by masking epitopes from immune surveillance. A prominent example is the (EGFR), an RTK whose extracellular domain comprises four subdomains (I-IV) that adopt a clamshell-like configuration upon binding. In the inactive state, subdomains II and IV tether to autoinhibit the receptor; (EGF) binding to the high-affinity site between subdomains I and III induces an extended conformation, exposing a dimerization arm in subdomain II to facilitate receptor pairing.

Transmembrane domains

Cell surface receptors are embedded in the plasma membrane through their transmembrane domains, which typically consist of one or more α-helical segments composed of hydrophobic residues that interact favorably with the bilayer's nonpolar core. These helices span the hydrophobic thickness of the membrane, approximately 20-30 long, ensuring stable integration via van der Waals interactions and hydrophobic effects with phospholipid tails. In -coupled receptors (GPCRs), the transmembrane domains form a characteristic bundle of seven α-helices (7TM), arranged in a compact barrel-like structure that connects the extracellular ligand-binding site to intracellular effectors. By contrast, many enzyme-linked receptors, such as receptor kinases (RTKs), possess a single-pass transmembrane α-helix, which serves as a minimal linker between their extracellular and intracellular domains. These structural variations in helical composition allow receptors to adapt to diverse signaling needs while maintaining membrane anchoring. The primary functions of transmembrane domains include anchoring the receptor within the plasma membrane to prevent and ensure at the cell surface. They also facilitate the transmission of conformational changes across the membrane, propagating ligand-induced alterations from the extracellular environment to intracellular signaling components without direct permeation of the hydrophobic barrier. In addition, these domains often contribute to receptor oligomerization, where helix-helix interactions stabilize dimeric or higher-order assemblies essential for and signal amplification. Transmembrane domains exhibit variations in topology, with single-span helices common in Type I receptors ( extracellular, intracellular, as in RTKs) and multi-span arrangements in serpentine receptors like GPCRs (Type III). β-Barrel transmembrane structures, formed by β-sheets rather than α-helices, are rare among eukaryotic cell surface receptors but occur in mitochondrial outer membrane proteins and serve as analogs to bacterial porins in functions. A key example is , a light-sensitive GPCR in rod cells, whose seven transmembrane α-helices form a tightly packed bundle that rotates and tilts upon photon absorption, enabling signal relay to the intracellular ; these dynamics have been characterized through spectroscopic techniques such as Fourier-transform infrared (FTIR) spectroscopy.

Intracellular domains

The intracellular domains of cell surface receptors, also referred to as cytoplasmic domains, consist primarily of tails and loops extending into the from the transmembrane segments. These regions often feature specific sequence motifs, such as Src homology 2 (SH2)-binding sites for phosphotyrosine recognition, proline-rich regions that interact with SH3 domains of proteins, and intrinsic kinase domains in enzyme-linked receptors. Many of these domains, particularly the C-terminal tails, exhibit unstructured or intrinsically disordered conformations, providing flexibility for dynamic interactions with intracellular effectors. Functionally, intracellular domains serve as platforms for recruiting signaling molecules upon receptor activation, including adapter proteins like , kinases such as Src family members, and heterotrimeric G proteins in the case of G protein-coupled receptors (GPCRs). They also contain sites susceptible to post-translational modifications, notably or serine/ , which modulate protein-protein interactions and signaling specificity. These domains interface directly with the transmembrane helices or segments to facilitate signal relay from the extracellular environment into the cell interior. Variations in intracellular domain architecture are evident across receptor classes. In GPCRs, the C-terminal tail and intracellular loops, particularly the third loop (ICL3), contain motifs for binding β-arrestins, which help in receptor desensitization and trafficking. In receptor kinases (RTKs), the intracellular portion typically includes a juxtamembrane region, a catalytic domain, and a C-terminal tail; the domain undergoes autophosphorylation on , creating docking sites for downstream effectors. A representative example is the , an RTK with a bilateral domain in its intracellular region that, upon , phosphorylates insulin receptor substrate (IRS) proteins at specific residues, enabling recruitment of signaling complexes.

Activation mechanisms

Ligand binding and conformational changes

Cell surface receptors initiate signaling by binding extracellular , which can occur at orthosteric sites—the primary binding pockets for endogenous —or allosteric sites, which are topographically distinct regions that modulate receptor function without directly competing for the orthosteric pocket. Orthosteric binding typically involves high-affinity interactions with specific chemical motifs on the , while allosteric binding enhances or inhibits this process through cooperative effects. The affinity of binding can be modulated by environmental factors such as , which influences hydrogen bonding networks in the binding pocket, or by ions like sodium, which stabilize or disrupt ionic interactions within the receptor. Additionally, co- binding at allosteric sites can alter orthosteric affinity through conformational propagation, as seen in G protein-coupled receptors (GPCRs) where sodium ions reduce binding potency. The equilibrium occupancy of receptors by ligands is quantitatively described by the Langmuir binding isotherm, which assumes a simple reversible interaction between a single ligand species and a homogeneous of binding sites: θ=[L]Kd+[L]\theta = \frac{[L]}{K_d + [L]} Here, θ\theta represents the fractional receptor occupancy, [L][L] is the concentration, and KdK_d is the , indicating the concentration at which half the receptors are occupied. This model provides a foundational framework for understanding binding saturation and is validated through equilibrium binding assays across various receptor types. Upon ligand binding, receptors undergo conformational changes that reposition structural elements to enable signal propagation. These rearrangements can involve rigid-body movements, such as the piston-like displacement of pore-lining helices in ligand-gated ion channels, which dilates the channel to permit ion flow. In contrast, GPCRs often exhibit twisting motions, including rotations of transmembrane helices that reorient intracellular loops. Such dynamics are commonly measured using , which detects distance changes between fluorophore-labeled sites in living cells, or , which resolves atomic-level motions in solution or membrane environments. Ligand binding can also induce or stabilize receptor dimerization or oligomerization, which is essential for activation in certain families. In receptor tyrosine kinases (RTKs), ligand binding promotes dimerization, bringing intracellular kinase domains into proximity for autophosphorylation. Conversely, some GPCRs exist as pre-formed dimers or oligomers on the cell surface, where ligand binding stabilizes these assemblies to facilitate conformational signaling. A representative example is the β₂-adrenergic receptor (β₂AR), a GPCR activated by epinephrine, where binding triggers an outward displacement of the cytoplasmic end of transmembrane helix 6 (TM6) by approximately 14 Å, as revealed by crystal structures of the active state. This movement, captured in epinephrine-bound β₂AR stabilized by a nanobody, exposes the G protein-binding interface while involving subtle inward shifts at the extracellular TM6 end to accommodate the ligand's hydroxyl group. These structural insights, derived from high-resolution , highlight how ligand-specific interactions drive conserved activation motifs across GPCRs.

Initial signal transduction steps

Upon receptor activation, typically triggered by ligand binding that induces conformational changes, intracellular domains of cell surface receptors become exposed, enabling the recruitment of downstream effector proteins to initiate signal transduction. This exposure creates specific binding sites for signaling molecules, such as SH2 or PTB domains in adaptor proteins, which dock onto phosphorylated residues within the receptor's cytoplasmic tail. In G protein-coupled receptors (GPCRs), for instance, the activated receptor serves as a guanine nucleotide exchange factor (GEF), facilitating the exchange of GDP for GTP on the Gα subunit of the heterotrimeric G protein, leading to its dissociation into active Gα-GTP and Gβγ subunits that propagate the signal. A key feature of these initial steps is signal amplification, where a single activated receptor can engage and activate multiple effector s, thereby generating a robust intracellular response from a limited extracellular stimulus. For example, in receptors, ligand-induced dimerization brings associated kinases (JAKs) into proximity, promoting their trans and subsequent phosphorylation of tyrosine residues on the receptor; this creates docking sites for signal transducer and activator of transcription (STAT) proteins, which are then phosphorylated by JAKs to initiate signaling without delving into full pathway elaboration. Such enzymatic cascades, including activations, allow exponential signal gain, as each activated can modify numerous substrates. Temporal dynamics play a crucial role in these initial transduction events, with responses ranging from rapid millisecond-scale activations—such as G protein dissociation and early second messenger production—to sustained minute-scale phosphorylations that maintain signaling fidelity. These kinetics are regulated by intrinsic timers like GTP hydrolysis on Gα subunits, which reverts the protein to its inactive state, ensuring transient signaling unless feedback mechanisms prolong it. Receptor further refines initial transduction through the formation of higher-order complexes, such as receptor mosaics or heterodimers, where allosteric interactions between proximate receptors integrate multiple inputs for coordinated signaling. For example, in GPCR heteromers, activation of one receptor can induce conformational changes in an adjacent partner within hundreds of milliseconds, modulating effector recruitment and preventing signal overload. This macromolecular organization allows cells to process convergent signals efficiently at the plasma membrane.

Classification of receptors

G protein-coupled receptors

G protein-coupled receptors (GPCRs) constitute the largest superfamily of cell surface receptors, comprising over 800 genes in the and playing pivotal roles in transducing extracellular signals into intracellular responses through indirect, metabotropic mechanisms. These receptors are integral to numerous physiological processes, with their activation leading to the modulation of second messenger systems via heterotrimeric G proteins. The structural hallmark of GPCRs is a bundle of seven α-helical transmembrane domains (7TM), connected by alternating intracellular and extracellular loops, which form a ligand-binding pocket and facilitate interactions with intracellular signaling partners. Based on , GPCRs are classified into six classes (A–F): class A (rhodopsin-like, the largest group), class B (secretin-like), class C (glutamate-like), class D (fungal pheromone receptors), class E (cAMP receptors in lower eukaryotes), and class F (/). This classification reflects evolutionary divergence and distinct ligand-binding modes, though classes A, B, C, and F predominate in humans. The activation mechanism of GPCRs begins with ligand binding to the extracellular orthosteric site, inducing a conformational shift in the 7TM bundle—particularly an outward movement of transmembrane helix 6—that exposes a -binding interface on the intracellular side. This enables the receptor to act as a (GEF), catalyzing the release of GDP from the Gα subunit of the (composed of Gα, Gβ, and Gγ) and its replacement by GTP.80117-8) The GTP-bound Gα then dissociates from Gβγ, allowing both components to engage downstream effectors such as , , or ion channels, thereby amplifying the signal. The cycle concludes with the intrinsic activity of Gα hydrolyzing GTP to GDP, promoting reassociation with Gβγ and terminating signaling; this hydrolysis occurs at a basal rate of approximately 0.05 s^{-1}, which can be accelerated by regulators of G protein signaling (RGS proteins). GPCRs mediate diverse sensory and regulatory functions, including vision (via opsin receptors like ), taste perception (through ~33 taste receptors), and olfaction (via ~400 olfactory receptors). Of the over 800 human GPCR genes, approximately 100 (or about 12%) are receptors, for which endogenous ligands remain unidentified, presenting opportunities for novel therapeutic targeting. Opioid receptors, such as the μ-, δ-, and κ-subtypes (class A GPCRs), exemplify their role in modulation by coupling primarily to Gi/o proteins, which inhibit and hyperpolarize neurons through Gβγ-mediated activation of potassium channels. Structural studies have advanced understanding of these receptors, with the 2007 of bovine providing early insights into the conserved 7TM fold and ligand-binding pocket in class A GPCRs. More recently, cryo-EM structures from the have captured active states of receptors bound to agonists and G proteins, revealing ternary complex formations that stabilize outward TM6 movement and inform biased for relief without side effects.

Ion channel-linked receptors

Ion channel-linked receptors, also known as ligand-gated channels (LGICs), are transmembrane proteins composed of multiple subunits that assemble to form a central -conducting pore. These receptors typically consist of three to five subunits, each featuring several transmembrane domains, with the overall often pentameric in the case of many eukaryotic LGICs. The extracellular domain contains the ligand-binding site, while the transmembrane segments line the pore, enabling selective upon activation. Activation occurs when a , such as a , binds to the extracellular domain, inducing conformational changes that propagate to the transmembrane region and open the pore, a process known as gating. These receptors exhibit high selectivity for specific ions, including cations like Na⁺, K⁺, and Ca²⁺ or anions like Cl⁻, determined primarily by the charge and size of residues in the pore-forming regions. The resulting ion flux generates rapid electrical signals, with conductance influenced by the and . Ion flow through these channels is quantitatively described by the Goldman-Hodgkin-Katz (GHK) equation, which models steady-state current under constant field assumptions: I=Pz2VF2RT[ion]in−[ion]oute−zVF/RT1−e−zVF/RTI = P z^2 \frac{V F^2}{RT} \frac{[\mathrm{ion}]_{\mathrm{in}} - [\mathrm{ion}]_{\mathrm{out}} e^{-z V F / R T}}{1 - e^{-z V F / R T}} where II is the current, PP is the permeability, zz is the ion valence, VV is the membrane potential, FF is Faraday's constant, RR is the gas constant, TT is temperature, and [ion]in[\mathrm{ion}]_{\mathrm{in}} and [ion]out[\mathrm{ion}]_{\mathrm{out}} are intracellular and extracellular ion concentrations, respectively. This equation highlights the voltage-dependent nature of ion conductance, essential for understanding rectification and reversal potentials in these receptors. These receptors play critical roles in fast synaptic transmission, operating on a millisecond timescale to propagate signals in the and at neuromuscular junctions. They contribute to neuronal excitability by depolarizing or hyperpolarizing cells through cation or anion influx, respectively, and are vital for processes like via excitation-contraction coupling. A prominent example is the (nAChR), a pentameric LGIC located at the that permits Na⁺, K⁺, and Ca²⁺ permeation upon binding. This receptor facilitates rapid synaptic transmission for muscle activation but undergoes desensitization, where prolonged exposure leads to channel closure despite presence, with fast desensitization kinetics characterized by time constants of approximately 70 ms.

Enzyme-linked receptors

Enzyme-linked receptors constitute a major class of cell surface receptors distinguished by their intrinsic enzymatic activity or association with enzymes in the intracellular domain. These receptors are typically single-pass transmembrane proteins, featuring an extracellular ligand-binding domain, a hydrophobic transmembrane , and an intracellular region with catalytic function. Key subtypes include receptor kinases (RTKs), which possess an intracellular kinase domain capable of phosphorylating residues, and receptor guanylyl cyclases, which convert GTP to the second messenger cyclic GMP (cGMP). Some receptors, such as class I receptors, lack intrinsic activity but associate noncovalently with kinases (JAKs), cytoplasmic kinases that enable enzymatic signaling upon activation. Activation of enzyme-linked receptors primarily occurs through ligand-induced dimerization or oligomerization, which brings the intracellular domains into proximity to initiate . In RTKs, this process facilitates trans-autophosphorylation, where the activated transfers the γ-phosphate from ATP to specific residues on the partner receptor or itself, generating phosphotyrosine docking sites; the Michaelis constant (Km) for ATP in these reactions typically ranges from 10 to 100 μM. These sites recruit adapter or effector proteins bearing Src homology 2 (SH2) domains, propagating signals through pathways like MAPK or PI3K. For guanylyl cyclases, binding induces a conformational shift that relieves autoinhibition of the cyclase domain, enhancing GTP cyclization without phosphorylation. In cytokine-JAK systems, dimerization activates JAK autophosphorylation, followed by phosphorylation of receptor tyrosines and downstream substrates like STAT transcription factors. These receptors orchestrate essential cellular functions, including proliferation, differentiation, migration, and . In humans, RTKs comprise 58 members distributed across 20 families, reflecting their broad involvement in developmental and physiological signaling. Receptor guanylyl cyclases, such as NPR-A (activated by ), regulate cardiovascular and renal functions via cGMP-mediated relaxation. receptors with JAKs control immune responses and hematopoiesis. A paradigmatic example is the (EGFR), an RTK where EGF binding promotes extracellular domain dimerization, culminating in asymmetric intracellular kinase dimer formation. Here, one kinase domain allosterically activates the receiver domain by displacing its activation loop (e.g., via interaction at residue L834), enabling ATP access and autophosphorylation to drive growth signaling.00584-8) This mechanism highlights how structural asymmetry ensures precise, ligand-dependent activation in RTKs.

Other receptor types

Adhesion receptors, such as , play a crucial role in mediating cell-matrix and cell-cell interactions, facilitating processes like migration, , and tissue organization. are heterodimeric transmembrane proteins composed of α and β subunits, with humans expressing 18 α subunits and 8 β subunits that form 24 distinct subtypes. These receptors enable bidirectional signaling: inside-out signaling activates through intracellular binding of talin to the β subunit cytoplasmic tail, promoting a conformational shift that increases affinity, while outside-in signaling transmits extracellular cues via clustering and adaptor protein recruitment. This dual mechanism supports essential functions in , immune modulation, and embryonic development. The (TNF) encompasses receptors that regulate cell survival, inflammation, and , with many members featuring intracellular death domains that initiate . Upon ligand binding, trimerization of these receptors recruits adaptor proteins like TRADD or through death domain interactions, forming signaling complexes that activate in the extrinsic apoptosis pathway or for survival signals. This superfamily modulates immune functions and tissue , with death domain-mediated serving as a key mechanism to eliminate damaged or infected cells. Notch receptors exemplify a unique class involved in cell-cell communication during development and differentiation, activated through a series of proteolytic cleavages triggered by binding.80417-7) Initial extracellular cleavage by metalloproteases (S2 site) releases a substrate for γ-secretase, which performs intramembrane proteolysis (S3/S4 sites) to liberate the Notch intracellular domain (NICD); this translocates to the nucleus, where it interacts with CSL transcription factors to drive target . The γ-secretase step is essential for signal propagation, ensuring precise spatiotemporal control in processes like and vascular patterning.80417-7)

Regulation of receptor function

Desensitization and phosphorylation

Desensitization of cell surface receptors refers to the rapid attenuation of signaling following activation, primarily achieved through events that uncouple the receptor from downstream effectors. In -coupled receptors (GPCRs), this process is mediated by GPCR kinases (GRKs), which selectively phosphorylate serine and threonine residues in the receptor's intracellular domains, particularly the C-terminal tail and third intracellular loop, upon binding. This creates high-affinity binding sites for β-arrestins, proteins that sterically hinder further coupling and thereby inhibit . The binding of β-arrestins to phosphorylated GPCRs not only blocks interaction but also prevents the receptor from adopting conformations necessary for sustained effector , such as stimulation in the case of Gs-coupled receptors. This mechanism operates on short timescales, typically seconds to minutes, and is classified as homologous desensitization when it is ligand-specific and restricted to the activated receptor subtype. In contrast, heterologous desensitization involves broader signaling inhibition through second messenger-dependent kinases, such as (PKA) or (PKC), which phosphorylate multiple receptor types independently of specific agonists, often leading to cross-talk between pathways. A well-characterized example is the β2-adrenergic receptor (β2-AR), where stimulation triggers GRK2 (also known as β-adrenergic receptor kinase 1) to phosphorylate multiple residues in the C-terminal tail. This phosphorylation recruits β-arrestin, rapidly uncoupling the receptor from Gs proteins and reducing cAMP production by approximately 60%. Such desensitization ensures precise temporal control of sympathetic signaling, preventing overstimulation in physiological contexts like cardiac response to catecholamines.

Trafficking, internalization, and degradation

Cell surface receptors, upon activation, often undergo trafficking processes that regulate their localization and abundance on the plasma . Internalization primarily occurs through clathrin-mediated (CME), where the adaptor AP-2 binds to the receptor's cytoplasmic tail and recruits to form coated pits. This process concentrates receptors into invaginating vesicles, which are then pinched off by the , whose provides the energy for membrane fission. of the receptor, often by kinases like PKC or receptor kinases themselves, can enhance recruitment to AP-2 and initiate this relocation. Following internalization, vesicles uncoat and fuse with early endosomes, where receptors are sorted based on post-translational modifications and interactions with Rab GTPases. Non-ubiquitinated or deubiquitinated receptors may enter pathways mediated by Rab11, returning to the plasma membrane via recycling endosomes to sustain signaling or restore surface levels. In contrast, ubiquitination—typically by ligases such as Cbl—tags receptors for degradation, directing them to intraluminal vesicles of multivesicular bodies (MVBs) through the endosomal sorting complex required for transport () machinery, including ESCRT-0, -I, -II, and -III complexes. This sorting commits receptors to late endosomes and eventual lysosomal fusion. Degradation occurs primarily in lysosomes, where MVBs fuse with the organelle, exposing receptors to hydrolytic enzymes that break down both the and receptor protein. Ubiquitinated receptor tails may also be degraded in the , while the bulk undergoes lysosomal , leading to down-regulation of surface receptor levels in responsive cells. A key example is the (EGFR): upon EGF binding, receptors internalize via CME within 2-5 minutes, with subsequent ubiquitination by Cbl directing about 50% to lysosomal degradation after sorting through early endosomes. This process terminates signaling and prevents overstimulation, with the remainder potentially recycling via Rab11 pathways.

Role in diseases

Mechanisms of receptor dysfunction

Cell surface receptor dysfunction can arise through various genetic and regulatory alterations that impair normal signaling, leading to pathological outcomes. These mechanisms broadly include loss-of-function and gain-of-function mutations, as well as dysregulation of receptor expression, trafficking, and interactions. Such disruptions alter the precise control of cellular responses, often resulting in aberrant activation or suppression of downstream pathways. Loss-of-function mutations reduce or eliminate receptor activity by compromising key structural or functional elements. For instance, frameshift mutations, caused by insertions or deletions of , disrupt the and often lead to truncated proteins with diminished binding or activation capabilities. Other mutations may affect , G-protein coupling, or , further impairing . These changes typically lower the receptor's ability to initiate signaling cascades, shifting cellular toward under-responsiveness. In contrast, gain-of-function mutations enhance receptor signaling, often conferring constitutive activity independent of presence. Point mutations in intrinsically disordered regions can stabilize the active conformation, for example, by creating new motifs that promote binding and alter localization. This hyperactivation bypasses normal regulatory checkpoints, amplifying downstream effects such as prolonged pathway engagement. Dysregulation through overexpression frequently occurs via , increasing receptor copy number and elevating surface density. This amplifies signaling by raising local concentrations, overwhelming inhibitory mechanisms like desensitization. Impaired trafficking, such as endocytic defects, reduces plasma membrane receptor levels by trapping proteins intracellularly or disrupting recycling. Ligand imbalances, often mediated by autoantibodies, can block binding sites or mimic ligands, distorting activation thresholds. These dysfunctions disrupt cellular , for example, by promoting uncontrolled proliferation through unchecked growth signals or enabling immune evasion via altered . Quantitative changes in receptor , normally ranging from 10³ to 10⁵ per cell, can lower signaling thresholds and amplify responses; overexpression may push densities beyond this range, intensifying pathological signaling. Such alterations parallel deviations from normal regulation, like phosphorylation-dependent desensitization, but persist unchecked.

Specific disease examples

Mutations in the (EGFR), a , are common drivers of non-small cell (NSCLC), with the L858R in exon 21 occurring in approximately 40-45% of EGFR-mutant cases and leading to constitutive activation of downstream signaling pathways that promote uncontrolled . This mutation enhances the activity of EGFR, resulting in increased autophosphorylation and signaling through the PI3K/AKT and MAPK pathways, often by 10- to 50-fold compared to wild-type EGFR in cellular assays. In breast cancer, amplification of the human epidermal growth factor receptor 2 (HER2, also known as ERBB2), an , occurs in 15-20% of cases and drives aggressive tumor growth by enhancing signaling through the same pathways, leading to poor prognosis if untreated. In metabolic disorders, mutations in the gene (INSR), which encodes an critical for , underlie type A insulin resistance syndrome, a rare condition characterized by severe , , and ovarian . These mutations, often heterozygous and affecting receptor autophosphorylation or trafficking, account for less than 1% of extreme cases, with prevalence estimates around 0.1-0.5% in populations screened for such syndromes. Neurological diseases frequently involve dysfunction of ion channel-linked and G protein-coupled receptors. The P23H mutation in , a essential for phototransduction in rod cells, is the most common cause of autosomal dominant (ADRP) in , affecting about 15% of ADRP cases and causing protein misfolding that triggers endoplasmic reticulum stress and photoreceptor . Variants in GABA_A receptors, ligand-gated ion channels that mediate inhibitory , have been identified in up to 1-2% of genetic epilepsies, with de novo mutations in subunits like GABRA1 or GABRG2 altering channel function, reducing inhibition, and contributing to developmental and epileptic encephalopathies. In immune disorders, gain-of-function mutations in the chemokine receptor , a that regulates leukocyte trafficking, cause WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis), a affecting approximately 1 in 4 million individuals. These mutations, typically truncating the C-terminal domain, impair receptor internalization and desensitization, leading to prolonged signaling upon binding, neutrophil retention in (myelokathexis), and recurrent bacterial infections. Recent investigations have implicated dysregulation of G protein-coupled receptors (GPCRs), particularly receptors, in the of , where rare variants or autoantibodies may contribute to persistent and symptoms like and through altered chemokine signaling.00411-6/fulltext) Computational analyses of GPCR-associated genes have highlighted pathways involving chemokine dysregulation as potential links to long COVID phenotypes, suggesting a role for receptor variants in prolonging post-viral effects.

Therapeutic applications

Structure-based drug design

Structure-based drug design (SBDD) utilizes atomic-level structural information of cell surface receptors to rationally develop small-molecule modulators that interact with high specificity and affinity. This approach has revolutionized drug discovery for receptors such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) by enabling the visualization of binding pockets and conformational dynamics essential for function. High-resolution techniques including X-ray crystallography, cryo-electron microscopy (cryo-EM), and nuclear magnetic resonance (NMR) spectroscopy generate three-dimensional models of receptor structures, often in complex with ligands or inhibitors, to guide iterative optimization of lead compounds. Computational methods complement experimental structures in SBDD by facilitating of vast chemical libraries and simulating receptor-ligand interactions. Molecular docking identifies potential binders by predicting how compounds fit into orthosteric or allosteric sites, while (MD) simulations explore dynamic behavior over time, including solvent effects and conformational flexibility. Free energy calculations, such as those using the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method, quantify binding strength through the equation: ΔG=−RTln⁡(Ki)\Delta G = -RT \ln(K_i) where ΔG\Delta G is the binding free energy, RR is the , TT is the absolute temperature, and KiK_i is the inhibition constant; these predictions help prioritize candidates for synthesis and testing. Targeting strategies in SBDD for cell surface receptors focus on orthosteric sites, where antagonists directly compete with endogenous ligands to prevent , or allosteric sites, where modulators bind remotely to stabilize inactive states, enhance selectivity, or induce biased signaling. In GPCRs, orthosteric antagonists occupy the central ligand-binding pocket formed by the seven transmembrane helices, while allosteric modulators often engage extracellular or intracellular regions to fine-tune without fully blocking the orthosteric site. Similar principles apply to RTKs, with orthosteric inhibitors targeting the ATP-binding cleft in the intracellular domain and allosteric agents modulating dimerization interfaces or loops. These strategies leverage receptor structures to avoid off-target effects and exploit disease-relevant conformations. The impact of SBDD is evident in the high proportion of approved drugs targeting cell surface receptors, with approximately 34% of U.S. (FDA)-approved drugs acting on GPCRs and over 500 such compounds identified by 2024. A key example involves the design of inhibitors for (EGFR), a ; crystal structures of EGFR domain mutants have enabled the development of selective inhibitors like , approved in 2015 for EGFR T790M-mutant non-small cell , with ongoing structural studies refining third-generation inhibitors as of 2025.

Targeted therapies and examples

Targeted therapies modulating cell surface receptors encompass inhibitors, monoclonal antibodies, bispecific antibodies, and emerging modalities like proteolysis-targeting chimeras (PROTACs) and therapies. These approaches aim to inhibit aberrant receptor signaling in diseases such as cancer, leveraging the receptors' extracellular accessibility for precise intervention. kinase inhibitors represent a cornerstone of for receptor kinases (RTKs), which are cell surface receptors driving oncogenesis. For instance, , an orally bioavailable reversible inhibitor, binds the ATP-binding site of the EGFR domain, blocking downstream signaling pathways like PI3K/AKT and MAPK that promote in non-small cell lung cancer (NSCLC). It is FDA-approved for first-line treatment of metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations, demonstrating improved compared to in clinical trials. Biologic therapies, including monoclonal antibodies, offer extracellular targeting of receptors to prevent ligand binding or dimerization. Trastuzumab, a humanized IgG1 monoclonal antibody, binds the juxtamembrane region of the HER2 (ErbB2) extracellular domain, inhibiting HER2 homodimerization and heterodimerization with other ErbB family members while promoting receptor internalization and degradation. This disrupts PI3K/AKT and MAPK signaling, leading to cell cycle arrest and apoptosis in HER2-overexpressing breast cancer; it is approved in combination with chemotherapy for early-stage and metastatic HER2-positive breast cancer, reducing recurrence risk by approximately 50%. Bispecific antibodies extend this by simultaneously engaging two targets, enhancing immune modulation of checkpoint receptors like PD-1. Cadonilimab, a PD-1/CTLA-4 bispecific antibody using a tetrabody format, blocks both checkpoints to boost T-cell activation while minimizing toxicity through asymmetric binding; it is approved in for recurrent or metastatic , showing an objective response rate of 33% in phase II trials. Other examples in advanced trials include ivonescimab (PD-1/VEGF), which combines PD-1 blockade with inhibition for NSCLC, achieving superior versus in phase III studies. Emerging PROTACs hijack the ubiquitin-proteasome system to degrade target receptors. For example, preclinical PROTACs targeting receptor tyrosine kinases like EGFR have shown promise in degrading mutant forms to overcome resistance in models as of 2025. therapies are also advancing to correct mutations in cell surface receptors. A prominent example of receptor-targeted cellular is chimeric antigen receptor (CAR) T-cell against , a B-cell surface serving as a proxy for B-cell receptor signaling in lymphoid malignancies. and , FDA-approved CAR-T products, redirect patient T cells to lyse -positive tumor cells, achieving complete remission rates of 80-90% in relapsed/refractory B-cell (B-ALL), with durable responses in over 50% of pediatric patients at five years.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK9866/
  2. https://www.ncbi.nlm.nih.gov/books/NBK554403/
  3. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/cell-surface-receptor
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC1885276/
  5. https://www.mdpi.com/journal/cells/special_issues/cell_receptors
  6. https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.0030101
  7. https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=694
  8. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/cell-surface-receptor
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3971589/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6738855/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC8721491/
  12. https://www.ncbi.nlm.nih.gov/books/NBK535431/
  13. https://www.nature.com/articles/321075a0
  14. https://www.nobelprize.org/prizes/chemistry/2012/press-release/
  15. https://pubmed.ncbi.nlm.nih.gov/30930094/
  16. https://www.nature.com/articles/s41392-023-01680-5
  17. https://www.researchgate.net/publication/5443553_The_leucine-rich_repeat_structure
  18. https://www.aimspress.com/article/doi/10.3934/biophy.2015.4.476?viewType=HTML
  19. https://raineslab.com/sites/default/files/labs/raines/pdfs/Attie1995.pdf
  20. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2015.00264/full
  21. https://www.jbc.org/article/S0021-9258%2817%2949566-4/pdf
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC8159107/
  23. https://www.nature.com/articles/s41392-024-01886-1
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2745238/
  25. https://www.researchgate.net/figure/EGFR-structure-and-ligand-binding-The-extracellular-domain-of-EGFR-has-4-subdomains-I_fig4_347949941
  26. https://www.nature.com/articles/aps2011171
  27. https://pubmed.ncbi.nlm.nih.gov/11815286/
  28. https://www.sciencedirect.com/science/article/pii/S0005273617300160
  29. https://www.sciencedirect.com/science/article/pii/S0021925817482949
  30. https://pubmed.ncbi.nlm.nih.gov/25315821/
  31. https://www.sciencedirect.com/science/article/pii/S0079610798000479
  32. https://www.sciencedirect.com/science/article/pii/S0065323303630032
  33. https://www.nature.com/articles/srep34129
  34. https://www.ncbi.nlm.nih.gov/books/NBK26822/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2914105/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4620971/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5503103/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC7913897/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4861465/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4092861/
  41. https://www.ncbi.nlm.nih.gov/books/NBK378978/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC2649814/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC4063350/
  44. https://www.mdpi.com/1422-0067/24/7/6187
  45. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158808
  46. https://www.sciencedirect.com/topics/neuroscience/ligand-binding
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC3000649/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC7060363/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6602575/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7483927/
  51. https://elifesciences.org/articles/37248
  52. https://www.sciencedirect.com/science/article/abs/pii/S1090780713002905
  53. https://www.sciencedirect.com/science/article/pii/S0026895X25152930
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC5398257/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC4441853/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3822040/
  57. https://www.ncbi.nlm.nih.gov/books/NBK10043/
  58. https://www.ncbi.nlm.nih.gov/books/NBK518966/
  59. https://www.nature.com/articles/s41392-021-00791-1
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC4477539/
  61. https://journals.biologists.com/jcs/article/123/24/4215/31387/G-protein-coupled-receptor-heteromer-dynamics
  62. https://www.nature.com/articles/s41392-024-01803-6
  63. https://www.nature.com/articles/s41392-023-01427-2
  64. https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC8738117/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC6535337/
  67. https://www.pnas.org/doi/10.1073/pnas.0304091101
  68. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1349097/full
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC11544303/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC10710086/
  71. https://www.sciencedirect.com/science/article/abs/pii/S0022283607003361
  72. https://www.sciencedirect.com/science/article/pii/S0092867423011807
  73. https://www.sciencedirect.com/science/article/pii/S2667325825003383
  74. https://www.sciencedirect.com/science/article/pii/S0969212613002438
  75. https://www.sciencedirect.com/science/article/pii/S0079610703000798
  76. https://rupress.org/jgp/article/149/10/911/43579/The-enduring-legacy-of-the-constant-field-equation
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC3315629/
  78. https://www.science.org/doi/10.1126/stke.2802005tr12
  79. https://www.nature.com/articles/aps201566
  80. https://www.nature.com/articles/aps200948
  81. https://onlinelibrary.wiley.com/doi/10.1111/gtc.12022
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC10701465/
  83. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2007-8-5-215
  84. https://www.nature.com/articles/cr2012103
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC5418412/
  86. https://www.nature.com/articles/1202568
  87. https://pubmed.ncbi.nlm.nih.gov/9688254/
  88. https://www.sciencedirect.com/science/article/pii/S1097276500804165
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC5533627/
  90. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00125/full
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC5591062/
  92. https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0707604
  93. https://www.nature.com/articles/s12276-023-01144-4
  94. https://pubmed.ncbi.nlm.nih.gov/7629102/
  95. https://www.atsjournals.org/doi/10.1165/ajrcmb.19.2.3025
  96. https://www.ahajournals.org/doi/10.1161/circheartfailure.112.966895
  97. https://journals.biologists.com/jcs/article/125/2/265/33132/The-role-of-ubiquitylation-in-receptor-endocytosis
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC7823896/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC2605728/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC3884125/
  101. https://www.sciencedirect.com/topics/immunology-and-microbiology/loss-of-function-mutation
  102. https://www.cell.com/cell/fulltext/S0092-8674(18)31120-6
  103. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0782-4
  104. https://autoimmunhighlights.biomedcentral.com/articles/10.1186/s13317-019-0125-5
  105. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/receptor-density
  106. https://www.pnas.org/doi/10.1073/pnas.1220050110
  107. https://pubmed.ncbi.nlm.nih.gov/24508693/
  108. https://pubmed.ncbi.nlm.nih.gov/8288049/
  109. https://pubmed.ncbi.nlm.nih.gov/1327927/
  110. https://pubmed.ncbi.nlm.nih.gov/35275162/
  111. https://pubmed.ncbi.nlm.nih.gov/37621067/
  112. https://pubmed.ncbi.nlm.nih.gov/36089616/
  113. https://pubmed.ncbi.nlm.nih.gov/23794067/
  114. https://www.researchgate.net/publication/383132945_Long_COVID_G_Protein-Coupled_Receptors_GPCRs_Associated_Genes_and_Pathways_as_a_Promising_Therapeutic_Potential_Through_Computational_Analysis
  115. https://www.creative-biostructure.com/structure-based-drug-design-sbdd-services.htm
  116. https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2024.1342179/full
  117. https://www.nature.com/articles/s42004-025-01542-x
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC4443793/
  119. https://www.mdpi.com/1420-3049/20/7/13384
  120. https://www.sciencedirect.com/science/article/pii/S2451945618302332
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC6556150/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC8895325/
  123. https://www.sciencedirect.com/science/article/pii/S104366182400519X
  124. https://www.sciencedirect.com/science/article/pii/S2162253124000829
  125. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01606
  126. https://www.nature.com/articles/s41573-024-00945-3
  127. https://www.ncbi.nlm.nih.gov/books/NBK554484/
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC3833260/
  129. https://pubmed.ncbi.nlm.nih.gov/11521720/
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC3092522/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC7964332/
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC10038071/
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC10501874/
  134. https://www.biochempeg.com/article/431.html
  135. https://www.nature.com/articles/s41573-023-00827-1
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11022988/
  137. https://pmc.ncbi.nlm.nih.gov/articles/PMC10786140/
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC7655016/
Add your contribution
Related Hubs
User Avatar
No comments yet.